Sep. 11 at 11:09 PM
$CMPX COMPANION-002 key data: ORR 18% vs 5.3% (p=0.02), PFS 4.7 vs 2.6mo (HR 0.44, p<0.0001). OS confounded by 54% crossover — ITT OS 8.9 vs 9.4mo (HR 1.05, NS).
BUT here's what matters: crossover patients were the SICKEST — progressing fastest on paclitaxel (PFS 1.9 vs 3.6mo, p=0.007). After tovecimig they lived 12.8 vs 6.1mo (HR 0.54, p=0.04). Sickest patients lived TWICE AS LONG.
That's not a statistical artifact. That's a survival signal that directly explains the confounded ITT OS.
Supporting context: Korean Ph2 (CTX-009, n=24) showed ORR 37.5%, DOR 6.9mo, OS 12.5mo. Durable responses confirmed.
Full COMPANION-002 DOR data at ESMO Oct 24. BLA Q4 2026.
